PrimeGene (Beijing) key facts
as of Oct 2026- Operator of an innovative pharmaceutical company intended to be specialized in innovative drug research, clinically valuable generic drug development and pharmaceutical industrialization.
- PrimeGene (Beijing) is valued at approximately $248.0M as of Oct 2026 (last reported valuation).
- It has raised $85.6M; the latest was Later Stage VC ($15.9M) in Jan 2025.
- Notable investors include Beijing State-owned Capital Operation and Management, K2VC, Shun Xi Fund, Lapam Capital, Capital Science and Technology Development Group — 8 tracked in total.
- Status: Privately Held (backing).
PrimeGene (Beijing)'s last reported valuation, Jan 2025. Nothing priced has surfaced since.
- ·Watch PrimeGene (Beijing): the Monday email on marks, rounds and moves
PrimeGene (Beijing) funding rounds
No funding rounds for PrimeGene (Beijing) are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
PrimeGene (Beijing) valuation
PrimeGene (Beijing)'s last reported valuation was $248 million in Jan 2025. No priced round, secondary trade or fund mark has surfaced since.
PrimeGene (Beijing) investors
8 investors are on record for PrimeGene (Beijing), including Beijing State-owned Capital Operation and Management, K2VC, Shun Xi Fund and Lapam Capital.
About PrimeGene (Beijing)
Operator of an innovative pharmaceutical company intended to be specialized in innovative drug research, clinically valuable generic drug development and pharmaceutical industrialization. The company focuses on new drug discovery, R&D and commercialization featuring immune/inflammatory diseases and external use, providing new drugs for skin, ophthalmology, rhinology and respiratory system.
- Sector
- Healthcare
- HQ
- Beijing, China
- Founded
- 2016
- Employees
- 90
- Website
- primegene.net/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.